This article is from: srnnews.com
Feb 26 (Reuters) – The U.S. Food and Drug Administration said on Thursday it approved Boehringer Ingelheim’s drug for patients with a type of advanced lung cancer who have received prior treatment, marking the second approval under the agency’s Commissioner’s National Priority Voucher pilot program.
(Reporting by Christy Santhosh in Bengaluru; diting by Tasim Zahid)
Brought to you by www.srnnews.com
